Literature DB >> 8674061

Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer.

K Hamada1, R Alemany, W W Zhang, W N Hittelman, R Lotan, J A Roth, M F Mitchell.   

Abstract

In most cervical cancers, the function of p53 is down regulated. To explore the potential use of p53 in gene therapy for cervical cancer, we introduced wild-type p53 into cervical cancer cell lines via a recombinant adenoviral vector, Ad5CMV-p53, and analyzed its effects on cell and tumor growth. The transduction efficiencies of all cell lines were 100% at a multiplicity of infection of 100 or greater. The p53 protein was detected in Ad5CMV-p53-infected cells. Protein expression peaked at day 3 after infection and lasted 15 days. The Ad5CMV-p53-infected cells underwent apoptosis, and cell growth was greatly suppressed. The Ad5CMV-p53 treatment significantly reduced the volumes of established s.c. tumors in vivo. These results indicate that transfection of cervical cancer cells with the wild-type p53 gene via Ad5CMV-p53 is a potential novel approach to the therapy of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 2.  The role of p53 in human cancer.

Authors:  D Malkin
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.

Authors:  Guido Schumacher; Marijke Oidtmann; Anne Rueggeberg; Dietmar Jacob; Sven Jonas; Jan-M Langrehr; Ruth Neuhaus; Marcus Bahra; Peter Neuhaus
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

4.  Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.

Authors:  Y Shao; Y Liu; C Shao; J Hu; X Li; F Li; L Zhang; D Zhao; L Sun; X Zhao; D J Kopecko; D V Kalvakolanu; Y Li; D Q Xu
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

5.  Cancer gene therapy using a survivin mutant adenovirus.

Authors:  M Mesri; N R Wall; J Li; R W Kim; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells.

Authors:  Yong-Seok Lee; Su-Mi Bae; Sun-Young Kwak; Dong-Chun Park; Yong-Wook Kim; Soo-Young Hur; Eun-Kyung Park; Byoung-Don Han; Young-Joo Lee; Chong-Kook Kim; Do Kang Kim; Woong-Shick Ahn
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

7.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

Review 8.  Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer.

Authors:  Momeneh Ghanaat; Nasser Hashemi Goradel; Arash Arashkia; Nasim Ebrahimi; Sajjad Ghorghanlu; Ziba Veisi Malekshahi; Esmail Fattahi; Babak Negahdari; Hami Kaboosi
Journal:  Acta Pharmacol Sin       Date:  2021-02-25       Impact factor: 6.150

9.  Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression.

Authors:  Amrendra K Ajay; Ankur K Upadhyay; Sandeep Singh; Maleppillil V Vijayakumar; Ratna Kumari; Vimal Pandey; Ramanamurthy Boppana; Manoj K Bhat
Journal:  Mol Cancer       Date:  2010-07-31       Impact factor: 27.401

10.  Gene Therapy Applications to Cancer Treatment.

Authors:  Susy M. Scholl; Silke Michaelis; Ray McDermott
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.